Concepts (120)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stomach Neoplasms | 2 | 2016 | 7 | 0.590 |
Why?
|
| Xylans | 2 | 2016 | 30 | 0.510 |
Why?
|
| Protective Agents | 1 | 2015 | 2 | 0.470 |
Why?
|
| Esophageal Neoplasms | 1 | 2015 | 4 | 0.470 |
Why?
|
| Iron | 1 | 2015 | 33 | 0.460 |
Why?
|
| Carcinoma, Ehrlich Tumor | 2 | 2019 | 9 | 0.430 |
Why?
|
| Saccharomyces cerevisiae | 2 | 2019 | 17 | 0.430 |
Why?
|
| Hematopoietic System | 1 | 2013 | 2 | 0.410 |
Why?
|
| Whole-Body Irradiation | 1 | 2013 | 3 | 0.410 |
Why?
|
| Hematologic Diseases | 1 | 2013 | 4 | 0.410 |
Why?
|
| Radiation Injuries | 1 | 2013 | 5 | 0.400 |
Why?
|
| Animals | 7 | 2019 | 1369 | 0.310 |
Why?
|
| Antineoplastic Agents | 1 | 2007 | 51 | 0.270 |
Why?
|
| Amphotericin B | 1 | 2004 | 1 | 0.230 |
Why?
|
| Embolism, Fat | 1 | 2004 | 1 | 0.230 |
Why?
|
| Fat Emulsions, Intravenous | 1 | 2004 | 1 | 0.230 |
Why?
|
| Phosphatidylcholines | 1 | 2004 | 1 | 0.230 |
Why?
|
| Phosphatidylglycerols | 1 | 2004 | 1 | 0.230 |
Why?
|
| Antifungal Agents | 1 | 2004 | 6 | 0.230 |
Why?
|
| Choristoma | 1 | 2004 | 1 | 0.220 |
Why?
|
| Duodenal Diseases | 1 | 2004 | 1 | 0.220 |
Why?
|
| Adenoma, Islet Cell | 1 | 2004 | 1 | 0.220 |
Why?
|
| Pancreatic Neoplasms | 1 | 2004 | 4 | 0.220 |
Why?
|
| Duodenal Ulcer | 1 | 2004 | 2 | 0.220 |
Why?
|
| Pancreas | 1 | 2004 | 16 | 0.220 |
Why?
|
| Mice | 5 | 2019 | 555 | 0.220 |
Why?
|
| Apoptosis | 3 | 2019 | 117 | 0.220 |
Why?
|
| Adenocarcinoma | 2 | 2019 | 28 | 0.190 |
Why?
|
| Melanosis | 1 | 2019 | 1 | 0.160 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2019 | 7 | 0.160 |
Why?
|
| Colonic Diseases | 1 | 2019 | 3 | 0.160 |
Why?
|
| Female | 5 | 2019 | 2964 | 0.150 |
Why?
|
| Methylnitronitrosoguanidine | 2 | 2016 | 4 | 0.150 |
Why?
|
| Rats, Wistar | 2 | 2016 | 38 | 0.150 |
Why?
|
| Treatment Outcome | 2 | 2013 | 402 | 0.140 |
Why?
|
| Stomach | 1 | 2016 | 6 | 0.130 |
Why?
|
| Carcinogenesis | 1 | 2016 | 9 | 0.130 |
Why?
|
| Free Radicals | 1 | 2015 | 2 | 0.120 |
Why?
|
| Oxidation-Reduction | 1 | 2015 | 17 | 0.120 |
Why?
|
| Organ Size | 1 | 2015 | 27 | 0.120 |
Why?
|
| Flow Cytometry | 3 | 2010 | 41 | 0.110 |
Why?
|
| Oxidative Stress | 1 | 2015 | 92 | 0.110 |
Why?
|
| Lip Neoplasms | 1 | 2013 | 2 | 0.110 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 2013 | 2 | 0.110 |
Why?
|
| T-Lymphocytes | 2 | 2010 | 14 | 0.100 |
Why?
|
| Radiation Dosage | 1 | 2013 | 5 | 0.100 |
Why?
|
| Gamma Rays | 1 | 2013 | 7 | 0.100 |
Why?
|
| Radiation Tolerance | 1 | 2013 | 4 | 0.100 |
Why?
|
| Radiation-Protective Agents | 1 | 2013 | 4 | 0.100 |
Why?
|
| Humans | 5 | 2019 | 4931 | 0.100 |
Why?
|
| Male | 4 | 2016 | 2620 | 0.100 |
Why?
|
| Immune System Diseases | 1 | 2010 | 2 | 0.080 |
Why?
|
| Nanofibers | 1 | 2010 | 2 | 0.080 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2010 | 4 | 0.080 |
Why?
|
| Cellular Senescence | 1 | 2010 | 6 | 0.080 |
Why?
|
| Adult | 2 | 2004 | 1402 | 0.080 |
Why?
|
| Thymus Extracts | 1 | 2009 | 4 | 0.080 |
Why?
|
| Spleen | 1 | 2009 | 12 | 0.080 |
Why?
|
| Aging | 1 | 2009 | 92 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 126 | 0.070 |
Why?
|
| Cytokines | 1 | 2007 | 60 | 0.070 |
Why?
|
| Cryptococcus neoformans | 1 | 2004 | 1 | 0.060 |
Why?
|
| Meninges | 1 | 2004 | 1 | 0.060 |
Why?
|
| Meningitis, Cryptococcal | 1 | 2004 | 2 | 0.060 |
Why?
|
| Injections, Intravenous | 1 | 2004 | 13 | 0.060 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2004 | 6 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2004 | 9 | 0.060 |
Why?
|
| Drug Combinations | 1 | 2004 | 15 | 0.060 |
Why?
|
| Drug Delivery Systems | 1 | 2004 | 10 | 0.060 |
Why?
|
| Drug Therapy, Combination | 1 | 2004 | 58 | 0.060 |
Why?
|
| Brain | 1 | 2004 | 78 | 0.060 |
Why?
|
| Cell Proliferation | 2 | 2019 | 101 | 0.060 |
Why?
|
| Peptic Ulcer Hemorrhage | 1 | 2004 | 1 | 0.060 |
Why?
|
| Radiography, Abdominal | 1 | 2004 | 1 | 0.060 |
Why?
|
| Immunoenzyme Techniques | 1 | 2004 | 10 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2004 | 43 | 0.050 |
Why?
|
| Biomarkers, Tumor | 1 | 2004 | 30 | 0.050 |
Why?
|
| Cell Line, Tumor | 2 | 2016 | 104 | 0.050 |
Why?
|
| Antigens, CD | 2 | 2010 | 16 | 0.040 |
Why?
|
| Killer Cells, Natural | 2 | 2010 | 34 | 0.040 |
Why?
|
| MCF-7 Cells | 1 | 2019 | 8 | 0.040 |
Why?
|
| DNA Damage | 1 | 2019 | 15 | 0.040 |
Why?
|
| Rare Diseases | 1 | 2019 | 4 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2019 | 14 | 0.040 |
Why?
|
| Esophagus | 1 | 2019 | 12 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2019 | 12 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2010 | 196 | 0.040 |
Why?
|
| Diet | 1 | 2019 | 95 | 0.040 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2016 | 6 | 0.030 |
Why?
|
| Gastric Mucosa | 1 | 2016 | 3 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2016 | 16 | 0.030 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2016 | 11 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2016 | 16 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2016 | 43 | 0.030 |
Why?
|
| Rats | 1 | 2016 | 373 | 0.030 |
Why?
|
| Lip | 1 | 2013 | 2 | 0.030 |
Why?
|
| Oral Ulcer | 1 | 2013 | 3 | 0.030 |
Why?
|
| Cytoplasm | 1 | 2013 | 6 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 7 | 0.030 |
Why?
|
| Epithelium | 1 | 2013 | 13 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2013 | 24 | 0.030 |
Why?
|
| Biopsy | 1 | 2013 | 23 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 45 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 202 | 0.030 |
Why?
|
| Housing, Animal | 1 | 2010 | 2 | 0.020 |
Why?
|
| Diamond | 1 | 2010 | 2 | 0.020 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2010 | 3 | 0.020 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2010 | 3 | 0.020 |
Why?
|
| Lectins, C-Type | 1 | 2010 | 4 | 0.020 |
Why?
|
| Platinum | 1 | 2010 | 4 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2010 | 20 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2010 | 16 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2010 | 17 | 0.020 |
Why?
|
| Cell Count | 1 | 2009 | 8 | 0.020 |
Why?
|
| Drinking | 1 | 2009 | 8 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2009 | 9 | 0.020 |
Why?
|
| Phenotype | 1 | 2009 | 62 | 0.020 |
Why?
|
| Dendritic Cells | 1 | 2009 | 23 | 0.020 |
Why?
|
| Middle Aged | 1 | 2013 | 1544 | 0.020 |
Why?
|
| Biomarkers | 1 | 2009 | 160 | 0.020 |
Why?
|